| (Values in U.S. Thousands) | Mar, 2018 | Dec, 2017 | Sep, 2017 | Jun, 2017 | Mar, 2017 |
| Sales | 5,930 | 1,670 | 50 | 70 | 110 |
| Sales Growth | +255.09% | +3,239.93% | -28.57% | -36.36% | -31.25% |
| Net Income | -2,110 | -1,890 | -6,070 | -8,540 | -24,080 |
| Net Income Growth | -11.64% | +68.86% | +28.92% | +64.53% | -56.87% |
Argos Therapeutics (ARGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States.